All of that genetic material that 23andMe has been collecting is finally being used for commercial drug development — specifically dermatological drugs.

The company inked an agreement with Spanish pharmaceutical developer Almirall, which concentrates on medical dermatology treatments, for the development of dermatological treatments based on an antibody developed by 23andMe.